AstraZeneca Pharma India Limited (the Company), a science-led biopharmaceutical company, today announced its full-year results for the financial year (FY) ended 31 March 2026. The Company maintained strong momentum during the year and delivered an impressive 33% year-on-year growth in total revenue, reflecting sustained performance across its therapy areas and continued progress in bringing innovative medicines to patients in India.

Financial Performance Summary

During FY 2025-26, AstraZeneca India recorded total revenue from operations of INR 22,755.8 Mn, supported by continued growth in Oncology and Biopharmaceuticals, as well as progress in Rare Disease. The year was also marked by 11 new regulatory approvals for medicines and indications, underscoring the Company’s commitment to scientific innovation, bringing them to the country at an accelerated pace and its focus on addressing unmet patient needs across India.

Key Highlights

Several important regulatory and business milestones were achieved during FY ’25-26, strengthening the Company’s portfolio and expanding patient access to innovative therapies in India. Notable approvals included Durvalumab for endometrial cancer, muscle invasive bladder cancer, and gastric cancer, among others. Additionally, Eculizumab was launched for the treatment of rare diseases, marking a significant milestone in this area.

Bhawana Agrawal, Chief Financial Officer & Director of the Company, said: “FY 2025-26 was a year of strong and consistent growth for AstraZeneca India, underpinned by the resilience of our business, the strength of our science-led portfolio, and disciplined execution across the organisation. Our performance reflects not only commercial momentum, but also our continued commitment to creating sustainable value through innovation, responsible growth, and meaningful impact for patients, society, and the planet.”

Praveen Rao Akkinepally, Managing Director, AstraZeneca India, added: “At AstraZeneca, science is at the heart of everything we do. Our FY 2025-26 performance reflects the progress we are making, accelerating the delivery of innovative medicines across key therapy areas and advancing our ambition to transform patient outcomes in India. With a strong pipeline and a clear sense of purpose, we remain focused on addressing unmet medical needs, advancing the healthcare ecosystem, and creating long-term impact through science-led innovation.”

Looking ahead, AstraZeneca Pharma India Limited remains committed to its mission of delivering great medicines to patients through innovative science and global excellence in development and commercialization.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

AstraZeneca moves sideways over three months, with neither buyers nor sellers taking control. The PEG stands at 4.78 — severely stretched. Any earnings miss could trigger a sharp de-rating. Thin margins at 9.2% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The stock holds at 45% of its 52-week range with RSI at 66. In other words, neither side has a clear edge right now. The business grows revenue at 28.6% and profits at 23.4%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 4.78 premium is usually justified. Check Fundamentals of AstraZeneca Pharma India Limited.